ALTH - I believe the EMEA rep was critical of the single arm. However since the FDA signed off on the SPA which permitted the single arm that shouldn't be a problem. Hard to figure this one out. FDA decision may not be a binary event ie another trial before approval or complete approval and the direction of the share price from such a decision is hard to predict IMO. In any case I think its close to being fully valued even on approval.
Market Data 
Markets 
AI
